Findings from a new study by Duke researchers are shifting the way one of the deadliest forms of lung cancer is understood and offering fresh insights that could revolutionize treatment approaches.

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells ...